Try our Advanced Search for more refined results

Expert Analysis

What FTC Is Saying In 1st Post-Actavis Pay-For-Delay Case

Law360, New York ( September 11, 2014, 12:13 PM EDT) -- On Sept. 8, 2014, the Federal Trade Commission filed a federal antitrust complaint in the United States District Court for the Eastern District of Pennsylvania against defendants AbbVie Inc. , Abbott Laboratories Inc. , Unimed Pharmaceuticals LLC, Besins Healthcare Inc. and Teva Pharmaceuticals Industries Inc. alleging violations of Section 5 of the FTC Act, 15 U. S. C. § 45(a), for entering into an agreement to maintain a monopoly over and restrain generic competition to AndroGel, a testosterone replacement therapy product. . . .

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!